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Abstract
Background: The major risk factor for the development of COPD is cigarette smoking. Smoking
causes activation of resident cells and the recruitment of inflammatory cells into the lungs, which
leads to release of pro-inflammatory cytokines, chemotactic factors, oxygen radicals and proteases.
In the present study evidence is found for a new cellular mechanism that refers to a link between
smoking and inflammation in lungs.
Methods: Employing human monocyte-derived macrophages, different techniques including FACS
analysis, Cytometric Bead Array Assay and ELISA were achieved to evaluate the effects of CS on
pro-inflammatory cytokine secretion including IL-8. Then, Toll-like receptor neutralization was
performed to study the involvement of Toll-like receptor-4 in IL-8 production. Finally, signaling
pathways in macrophages after exposure to CS medium were investigated performing ELISA and
Western analysis.
Results: We demonstrate that especially human monocytes are sensitive to produce IL-8 upon
cigarette smoke stimulation compared to lymphocytes or neutrophils. Moreover, monocyte-
derived macrophages produce high amounts of the cytokine. The IL-8 production is dependent on
Toll-like receptor 4 stimulation and LPS is not involved. Further research resolved the cellular
mechanism by which cigarette smoke induces cytokine production in monocyte-derived
macrophages. Cigarette smoke causes subsequently a concentration-dependent phosphorylation of
IRAK and degradation of TRAF6. Moreover, IκBα was phosphorylated which suggests involvement
of NF-κB. In addition, NFκB -inhibitor blocked cigarette smoke-induced IL-8 production.
Conclusion:  These findings link cigarette smoke to inflammation and lead to new insights/
therapeutic strategies in the pathogenesis of lung emphysema.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a
multicomponent disease [1,2] and is associated with an
airway inflammatory profile consisting mainly of an
increased number of CD8+T cells, macrophages, and neu-
trophils [3-5]. The major risk factor for the development
of COPD is cigarette smoking. Smoking causes activation
of resident cells and the recruitment of inflammatory cells
into the lungs, which leads to release of pro-inflammatory
cytokines, chemotactic factors, oxygen radicals and pro-
teases [6]. Airway inflammation in COPD involves
inflammatory mediators such as interleukin (IL)-8 and
tumor necrosis factor (TNF)-α which are generally consid-
ered to be important mediators in neutrophil recruitment
[7-9]. Many observations suggested macrophages to be
the orchestrators of chronic response and tissue destruc-
tions in COPD [10-12]. For instance, macrophages in
broncho alveolar lavage (BAL) from asymptomatic smok-
ers and patients with COPD are higher than in BAL from
nonsmokers [13]. Macrophages produce cytokines
including IL-8 and the levels of IL-8 in induced sputum
are correlated with the extent of inflammation and sever-
ity of COPD [14]. In alveolar cells, cigarette smoke (CS)
constituents induce mRNA expression of inflammatory
cytokines like IL-1α, IL-1β, and IL-6 [15]. Moreover, cul-
tured human bronchial epithelial cells [16] and alveolar
macrophages [17] release IL-8 in response to CS medium
prepared by bubbling smoke through cell culture
medium.
The Toll-like receptors (TLRs) are an evolutionarily con-
served family of cell surface molecules which participate
in innate immune response[18]. Among TLR family the
best described and most studied is TLR2 and TLR4. TLR2
and TLR4 are shown to be expressed maximally in CD14
positive mononuclear cells within fractionated peripheral
blood leukocytes [19]. Activation of macrophages
through the TLR4 signal transduction pathway leads to
nuclear factor (NF)-κB activation and the production of
pro-inflammatory mediators like IL-8 [20]. Since CS may
provide many potential inflammatory stimuli and the role
of TLR proteins in inflammatory airway diseases, such as
asthma and allergy is being intensively studied [21], we
hypothesized that CS medium may contribute to the
pathogenesis of COPD by stimulation of macrophages
through ligation of TLRs. To examine the objection,
firstly, the effects of CS on pro-inflammatory cytokine
secretion including IL-8 were evaluated. Then, the
involvement of TLR2 and TLR4 in IL-8 production was
studied and, finally, signaling pathways in human mono-
cyte-derived macrophages after exposure to CS medium
were investigated. The findings explain the possible mech-
anisms behind the initial inflammatory process in lungs.
Methods
Isolation of PBMC and culture of human monocyte-
derived macrophages
Peripheral blood mononuclear cells (PBMC) were sepa-
rated [22] by density gradient centrifugation (Pharmacia
Biotech, Uppsala, Sweden) of buffy coats obtained from
normal blood donors. Thereafter, neutrophils were pre-
pared [23] by centrifugation on a Percoll density gradient
(purity 90%). The remained cells used for preparation of
lymphocyte fraction by centrifugation on a Percoll density
gradient (purity 85%). Human blood monocytes were
obtained using RosetteSep™ (Stem cell Technologies)
according to manufacturer's instructions. Briefly, fresh
blood was incubated with RosetteSep™ cocktail at room
temperature followed by Ficoll-Paque gradient centrifuga-
tion (Life Technologies, Cergy Pontoise, France). The
enriched monocytes were collected from the Ficoll:plasma
interface and purity was assessed by FACS analysis using a
FITC-labeled anti-CD14 mAb (95%). Macrophages were
obtained by culturing monocytes for 5 days in medium
containing 2.5 ng/ml GM-CSF and 25 ng/ml M-CSF
(R&D), as described before [24].
CS medium preparation
CS medium was prepared as described before [25,26].
Briefly, a smoking machine (Teague Enterprises, Davis,
CA, USA) was used to direct main and side stream smoke
from one cigarette through 5 ml culture medium (RPMI
without phenol red). Hereafter, absorbance was measured
spectrophotometrically and the media was standardized
to a standard curve of CS medium concentration against
absorbance at 320 nm. This concentration was serially
diluted with untreated media and applied to the cells.
Freshly prepared CS medium was used in all experiments.
Nontoxic concentrations of CS medium were detected
performing different toxicological assays (SRB, WST-1,
and LDH) and FACS analysis (annexin-V and 7-AAD
staining).
Quantification of human cytokines
Cells were plated at a density of 5 × 105 cells/ml in 96-well
cell culture plates and stimulated with different concen-
trations of CS medium or LPS (as positive controls) for
overnight. In defined experiments, cells were pretreated
with SB 203580 (5 µM) or curcumin (25 µM) (both from
Calbiochem) for 30 min before stimulation with CS
medium. Hereafter, supernatants were collected and
stored at -20 C prior to cytokine quantification. Commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kits (R&D systems) or Cytometric Beads Array
(CBA) kits (BD Biosciences) were used to quantify
cytokine secretion according to the manufacturer's
instructions. For CBA, analyses were run on a FACSCali-
bur®. Quadruplicate samples were mixed and used as a
sample for the assay.Respiratory Research 2006, 7:66 http://respiratory-research.com/content/7/1/66
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Intracellular cytokine staining
1 × 106 cells/ml were stimulated by different concentra-
tions of CS medium and were incubated for 5 h in the
presence of the protein transport inhibitor GolgiStop™
(Pharmingen, San Diego, CA, USA). Next, cells were
stained for surface antigens prior to fixation by a 4% para-
formaldehyde solution. After 24 hours, the cells were per-
meabilized in Cytofix/Cytoperm™ solution and stained
for intracellular cytokine expression (all from Pharmin-
gen, San Diego, CA, USA).
Anti-TLR neutralization of cytokine production
Cells were incubated with anti-human TLR2 (clone TL2.1)
or mouse IgG2a isotype control (20 µg/ml), for 30 min at
room temperature or with anti-human TLR4 (clone
HTA125) or mouse IgG2a isotype control (20 µg/ml), (all
from eBioscience, CA, USA) for one hr at 37°C. Hereafter,
cells were stimulated with different concentrations of CS
medium or LPS or PMA/ionomycin (Sigma) and incu-
bated overnight. Supernatants were collected and stored
at -20°C prior to cytokine quantifications.
Western analysis
Treated cells were lysed in ice-cold buffer (containing 50
mM Tris (pH 8.0), 110 mM NaCl, 5 mM EDTA, 1% Triton
X-100, and 100 µg/ml PMSF) and protein concentrations
were determined performing Bradford assay. Whole cell
lysates were boiled in equal volumes of loading buffer
(125 mM Tris·HCl, pH 6.8, 4% SDS, 20% glycerol, and
10%2-mercaptoethanol) and 50 µg of proteins loaded per
lane on an 8–16% Tris-glycine gradient gel (Novex, San
Diego, CA). Proteins were electrophoretically separated
and transferred to nitrocellulose membranes (Novex)
using the Novex Xcell Mini-Gel system. For immunoblot-
ting, membranes were blocked with 10% non-fat dried
milk in Tris-buffered saline (TBS). Primary antibodies
against human IκBα, phospho IκBα, human IRAK, and
human TRAF (Santa Cruz Biotechnology) and appropri-
ate peroxidase-conjugated secondary antibodies (Calbio-
chem, La Jolla, CA) were applied. Blots were incubated in
commercial enhanced chemiluminescence reagents (ECL;
Amersham, Buckinghamshire, England), and exposed to
photographic film. Films were analyzed on a GS7–10 Cal-
ibrated Imaging Densitometer equiped with Quantity
One v. 4.0.3 software (Bio-Rad Laboratories, Veenendaal,
The Netherlands).
Preparation of cytoplasmic and nuclear extracts
Cells were washed twice with PBS and allowed to equili-
brate for 5 min in the ice-cold cytoplasmic extraction rea-
gent (Pierce) containing protease inhibitors (MiniTM
protease inhibitors, cocktail). Thereafter, cells were lysed
and the supernatant (the cytoplasmic extracts) were col-
lected and frozen at -70°C. To obtain the nuclear extracts,
the pellets were suspended in the nuclear extraction buffer
containing protease inhibitors. The solution was clarified
by centrifugation at 14,000 g for 5 min after a vigorous
mixing and 10 min incubation on ice. The supernatant
(nuclear extracts) was collected and stored at -70°C. Pro-
tein concentrations were determined using a BCA protein
assay kit (Pierce). The lysates (30 mg) from cytoplasmic or
nuclear fractions were subjected to SDS/PAGE [10% (w/v)
gel] for detection of P65 or actin expression.
Statistic analysis
Unpaired Student's t tests (two-tailed) were performed
using GraphPad PRISM software (version 4.00 for Win-
dows; GraphPad, San Diego, CA). A value of p < 0.05 was
considered significant. The error bars in the bar graphs
show the SEM.
Results
Human monocyte-derived macrophages produce IL-8 in 
response to CS medium
Because little is known about the activation of primary
human cells by CS medium, an exploratory study was per-
formed measuring several inflammatory cytokines which
are also known to be involved in COPD. PBMC stimu-
lated by CS medium produced inflammatory cytokines
such as high amounts of IL-8 (5 ng/ml) (data not shown).
Further experiments showed that monocytes in compari-
son with neutrophils and lymphocytes are the major
source of IL-8 generation in PBMC (Fig. 1A). In addition,
high expression of intracellular IL-8 was demonstrated in
CD14 positive cells (Fig. 1B). Since these findings sug-
gested that most likely monocytes are the major source of
IL-8 production after exposure to CS medium, a human
monocyte-derived macrophage culture system was estab-
lished. Purified monocytes were cultured for 5 days in
medium containing GM-CSF and M-CSF to gain macro-
phages [24]. Macrophages showed responsiveness to CS
medium in a dose dependent manner and released pro-
inflammatory cytokines e.g. IL-6, IL-8 and TNF-α(Fig. 2A).
Intracellular cytokine staining demonstrated high levels
of IL-8 expression in human macrophages after 5 hr stim-
ulation with CS medium (Fig. 2B).
CS medium-induced IL-8 production by human monocyte-
derived macrophages is TLR-4 mediated
CS may contain bacterial endotoxin [27] and many other
different inflammatory stimuli. We analyzed the samples
for endotoxin biological activity using the Limulus assay.
The amount of endotoxin in the applied CS medium was
less than 3 pg/ml (data not shown). Then macrophages
stimulated with polymyxin bead treated CS medium. The
amount of IL-8 release just varied from 21.6 ± 1.02 ng/ml
to 19.8 ± 3.6 ng/ml when the medium was treated with
polymyxin beads (data not shown). Thereafter, the
involvement of TLR2 or TLR4 in CS medium-induced IL-
8 production by macrophages was investigated. Pretreat-Respiratory Research 2006, 7:66 http://respiratory-research.com/content/7/1/66
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ment of macrophages with anti-human TLR4, markedly
blocked IL-8 secretion in response to CS medium (Fig. 3A)
while no inhibition was observed when the cells were pre-
incubated with anti-human TLR2 or mouse IgG2a isotype
control (Fig. 3B). Moreover, anti-human TLR4 failed to
inhibit PMA/ionomycin-induced IL-8 generation by mac-
rophages (Fig. 3A).
CS medium-induced signaling pathways in human 
monocyte-derived macrophages are IRAK and TRF6 
mediated
In the TLR-mediated signaling pathways, IRAKs and
TRAF6 play critical roles, as demonstrated by analysis in
gene targeted mice [28]. Activation of IRAK shown to be
the first event downstream of recruitment of the adaptor
In PBMC, human monocytes are the major source of IL-8 production in response to CS medium stimulation Figure 1
In PBMC, human monocytes are the major source of IL-8 production in response to CS medium stimulation. a) Different frac-
tions of peripheral blood cells were isolated and stimulated with different concentrations of CS medium. Cytometric Beads 
Array assay was performed. Data represent the mean ± SD of two experiments conducted with different PBMC preparations. 
b). Human PBMC were left in culture medium (A) or were stimulated for 6 hours with CS medium (B) or LPS (C) in the pres-
ence of GolgiStop™. The cells were stained for surface marker CD14 and intracellular IL-8 expression. The data reflect gating 
on monocytes, based on forward and side scattered light signals. The result shown is a representative of two experiments con-
ducted with different PBMC preparations that had similar results.
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molecule MYD88 in the TLR4 signaling pathways [29]. CS
medium treated macrophages showed IRAK phosphoryla-
tion after a 45 minute exposure of CS medium (Figure
4A). TRAF6 is a critical component of TLR4-mediated sig-
naling pathways at level downstream of IRAK [28,30].
Western analysis showed that CS degrades TRAF6 after 1hr
exposure to human macrophages and complete degrada-
tion achieved after a 3hr-treatment of the cells with the
smoke medium (Figure 4B).
CS medium stimulation of human monocyte-derived 
macrophages leads to NF-κB activation
TLR-mediated signaling pathways via IRAK and TRAF6
leads to NF-κB activation [28]. To investigate whether NF-
κB activation is also involved in IL-8 secretion by human
monocyte-derived macrophages after CS stimulation,
cells were treated with increasing concentrations of CS
medium and whole-cell extracts were immunoblotted for
phosphorylated IκB. As shown in Figure 5a, an increase in
phosphorylated IκB levels was observed after exposure to
CS medium. In contrast, stabilized IκB levels was demon-
strated as macrophages pretreated with proteasome inhib-
itor, MG-132, for one hour before exposure to CS (Fig.
5A). Moreover, we examined the involvement of NF-κB in
CS-induced IL-8 production by treatment of macrophages
for 30 min with NF-κB inhibitor curcumin prior to CS
medium exposure (Fig. 5B). We found inhibition of IL-8
release by 85% (from ~52.5 ± 7 ng/ml to ~4.2 ± 0.3 ng/
After exposure to CS medium, human monocyte-derived macrophages produce IL-8 Figure 2
After exposure to CS medium, human monocyte-derived macrophages produce IL-8. a) Macrophages were stimulated over-
night with different concentrations of CS medium. Cytometric Bead Array assay was performed to quantify cytokine secretion. 
Representative dot plots of #1. IL-8, #2. IL-1β, #3. IL-6, #4. IL-10, #5. TNF-α, and #6. IL-12. b) Cells were stimulated with CS 
medium (OD = 0.03) for 5 h in the presence of GolgiStop™. The cells were stained for intracellular IL-8 expression. The result 
is a representative of five experiments conducted with different human monocyte-derived macrophage preparations that had 
similar results.
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ml) after pretreatment of macrophages with curcumin at
concentration of 25 µM. Next, we incubated the cells with
p38 MAP kinase inhibitor SB 203580. SB 203580 at con-
centration of 5 µM inhibited the IL-8 generation by mac-
rophages. The amounts of IL-8 produced and released by
the cells were diminished by 42% (from ~52.5 ± 7 ng/ml
to ~22.0 ± 5.1 ng/ml). Furthermore, we studied the trans-
location of NF-κB subunit p65 to the nucleus following
CS activation. As shown in Figure 5C an increase in p65
level was detected in the CS stimulated sample. In con-
trast, p65 level in nuclear extracts was not detected upon
anti-TLR4 antibody treatment of the cells prior to CS
exposure.
Discussion
The mechanisms responsible for induction of inflamma-
tory reactions by CS have yet to be elucidated. We used a
medium collected from main stream and side stream of
CS to stimulate human monocyte-derived macrophages.
The present study shows for the first time that macro-
phages can be stimulated by CS in a dose dependent man-
ner (Figure 1 and 2) to produce cytokines which is
mediated by a cascade of TLR4 signaling events (Figure 3).
IL-8 production by human macrophages is TLR4 mediated Figure 3
IL-8 production by human macrophages is TLR4 mediated. a) Cells were incubated overnight with anti-TLR4 or isotype control 
prior to CS medium or LPS or PMA/ionomycin exposure. IL-8 production was quantified using ELISA. The result is a repre-
sentative of 3–5 experiments conducted with different human monocyte-derived macrophage preparations in which the mean 
fold increase in IL-8 production at concentration of CS = 0.03 was 1.8 ± 0.31 (n = 5) and the mean percentage of reduction in 
IL-8 production in the presence of the anti-TLR4 antibody was 66.7 ± 8.6 (n = 5). b) Cells were incubated with anti-TLR2 or 
anti-TLR4 prior to CS medium exposure and Cytometric Beads Array assay was performed. The result is a representative of 3 
experiments conducted with different human monocyte-derived macrophage preparations that had similar results.
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Because of the high levels of IL-8 generation by cultured
macrophages (Figure 2), IL-8 secretion was monitored to
study the mechanisms by which CS medium induced
inflammatory cytokines. First we investigated whether or
not the effect is due to LPS that might be present CS
extract? We analyzed the samples for endotoxin biological
activity using the Limulus assay. The amount of endotoxin
in the applied CS medium was less than 3 pg/ml, which is
most likely not enough to trigger the cytokine production
by human macrophages. Polymixin B is an antibiotic that
contains a cationic cyclopeptide with a fatty acid chain
that can neutralize the biological activity of endotoxins by
binding to the lipid A portion of the bacterial LPS [31-33].
We exposed the cells to CS medium which has been
treated with polymixin beads. Macrophages stimulated
with polymyxin bead treated CS medium did not show a
significant decrease in the amounts of IL-8 generation
(data not shown). The amount of IL-8 release in response
to CS medium just varied from 21.6 ± 1.02 ng/ml to 19.8
± 3.6 ng/ml when the medium was treated with poly-
myxin beads demonstrating that the effects of CS is not
due to LPS presents in the medium.
Since CS extract contains many inflammatory stimuli, two
well described TLRs, TLR2 and TLR4 which are expressed
in human macrophages, were studied. We found that neu-
tralization of TLR4 but not TLR2 inhibits CS medium-
induced IL-8 secretion by human macrophages (Figure 3).
The discrepancy can be explained by the recent report sug-
gesting that the functional outcomes of signaling via TLR2
or TLR4 are not equivalent and in spite of their shared
capacities to activate the same signaling molecules, differ-
ent TLRs are capable of activating distinct cellular
responses [34].
The possibility of changes in cellular behavior of macro-
phages after incubation with TLR4 neutralizing antibody
was studied. The amounts of IL-8 release after stimulation
with PMA/ionomycin was monitored (Figure 3). PMA
stimulates PKC and ionomycin increases intracellular cal-
cium [35]. The cytokine production by human monocyte-
derived macrophages is modulated by PKC [36]. We pre-
treated the cells with anti-human TLR4 antibody before
CS medium exposure and examined the amounts of IL-8
generation. We demonstrated that macrophages produce
IL-8 in response to PMA/ionomycin and the amount of IL-
8 release is not affected by TLR4 neutralizing antibody
(Figure 3A). Indeed, the same levels of IL-8 production by
macrophages following PMA/ionomycin stimulation in
the presence or absence of neutralizing antibody suggest
that Anti-TLR4 inhibition of CS-induced IL-8 release is not
due to cellular damage but blockade of TLR4. Then, TLR4
and its downstream pathways were studied. TLR4 ligation
leads to NF-κB activation and signals via IRAK and TRAF
[29,30]. Our observations show that the signaling cascade
of TLR4 ligation by CS medium involves IRAK-1 phos-
phorylation (Figure 4A). Additionally, we found that
TRAF6 degradation is also involved in the signaling path-
ways (Figure 4B). Ligation of TLR4 by LPS activates NF-κB
and induces production of cytokines in human myeloid
cells [37]. Moreover, induced transcriptional activity of
NF-κB leads to maximal amount of IL-8 generation (19).
We demonstrated increases in phosphorylated IκB-α lev-
els after CS medium stimulation of macrophages (Figure
5A). The proteosome inhibitor MG-132 blocks the degra-
dation of IκB-α [38]. As shown in Figure 5A, an increase
in the phospho- IκB-α level was detected in the CS-treated
samples (see lanes cells and cells plus CS). In contrast, the
samples pretreated with MG-132 did not show such levels
of phospho- IκB-α upon CS stimulation. Moreover, the
degradation of IκB-α is blocked when the cells were
exposed to MG-132 (lanes MG-132). The natural product
curcumin is a known inhibitor of activation of NF-κB.
CS medium triggers signaling pathways mediated IRAK and  TRAF in human monocyte-derived macrophages Figure 4
CS medium triggers signaling pathways mediated IRAK and 
TRAF in human monocyte-derived macrophages. a) Macro-
phages were treated with CS medium or LPS for 45 minutes 
and IRAK activation was monitored by western blot analysis. 
The figure shows autophosphorylation of IRAK (p-IRAK). B) 
TRAF6 degradation was determined after 1 to 3 hrs CS 
medium or LPS exposure to macrophages. Cells were lysed 
and western analysis was performed. The result shown is a 
representative of two experiments conducted with different 
human monocyte-derived macrophage preparations that had 
similar results.
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Involvement of NF-κB in CS-induced IL-8 production was
demonstrated when macrophages were treated with NF-
κB inhibitor curcumin prior to CS medium exposure. Cur-
cumin completely blocked the CS induced IL-8 produc-
tion (Fig. 5B). The anti-inflammatory properties of
curcumin and its ability to inhibit the immune response
NF-κB involvement in CS medium stimulation of human macrophages for IL-8 production Figure 5
NF-κB involvement in CS medium stimulation of human macrophages for IL-8 production. a). Cells were left in culture medium 
or incubated with proteasome inhibitor, MG-132, at 10 µM for 1 hr prior to a 45 minute treatment with CS medium or LPS. 
Macrophages were lysed to determine IκB-α and phosphorylated IκB-α. b). Macrophages were treated for 30 min with SB 
203580 (5 µM) and curcumin (25 µM) prior to CS medium exposure. IL-8 production was quantified using ELISA. c). Cells 
were left in culture medium or incubated with anti-TLR4 or isotype control prior to a 30 minute exposure to CS or LPS. 
Nuclear proteins were extracted, subjected to 10 % SDS-PAGE, and blotted with P65 Abs. The result shown is a representa-
tive of three experiments conducted with different human monocyte-derived macrophage preparations that had similar results.
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upon exposure to a variety of external stimuli may, at least
in part, result from inhibition of the activation of NF-κB
by these external signals, since many of the genes that are
implicated in the immune/inflammatory response are up-
regulated by NF-κB. For example, curcumin inhibits the
LPS-induced production of IL-1β and TNF-α which NF-κB
is implicated in these signaling pathways [39]. SB 203580
is an inhibitor of p38 MAP kinase. Recently, significant
advances in the understanding of signaling pathways,
which coordinately regulate IL-8 transcription as well as
mRNA stabilization in response to external stimuli, have
been made. The maximal IL-8 amounts can only be gen-
erated if the resulting mRNA, after NF-κB translocation, is
rapidly stabilized by the p38 MAPK pathway[40]. Block-
ing the p38 MAPK pathway by SB203580 decreased the
amount of IL-8 generation suggesting that p38 MAPK
pathway involves in the maximal amounts of IL-8 produc-
tion after CS exposure. More studies are needed to demon-
strate that whether the role of p38 MAPK pathway is to
stabilize IL-8 mRNA after CS stimulation or the pathway
at least partially activates NF-κB activation. It has been
demonstrated that SB203580 attenuates lysophosphatidic
acid-dependent phosphorylation of I-κB, NF-κB and NF-
κB transcription in human bronchial epithelial cells [41].
These findings suggest that SB203580 by itself might be
involved in NF-κB activation. The increases in phosphor-
ylated IκB-α levels as well as the dramatic decline in
amount of IL-8 secretion by NF-κB inhibitor (see above)
showed that NF-κB activation is involved in the pathways
of CS stimulation of human macrophages.
The five members of the mammalian NF-κB family, p65
(RelA), RelB, c-Rel, p50/p105 (NF-κB1), and p52/p100
(NF-κB2), exist in unstimulated cells as homo- or het-
erodimers bound to I-κB family proteins. NF-κB activa-
tion leads to the translocation of thetranscription factors
from the cytoplasm to the nucleus. [42,43]. We studied
the translocation of NF-κB subunit p65 to the nucleus fol-
lowing CS activation. We detected an increase in p65 level
in nuclear protein extracts following CS exposure (Figure
5C). Furthermore, no p65 was detected in the nuclear pro-
tein extracts where the cells were pre-treated with anti-
TLR4 prior to CS medium stimulation (Figure 5C). These
findings confirm that CS induces NF-κB translocation to
the nucleus and that this can be inhibited by blockade of
TLR4.
In conclusion, the results presented here show that the
mechanism underlying IL-8 production by human macro-
phages after CS medium exposure involves activation of
TLR4 specific signaling pathways. It has to be stressed at
this point that a secreted TLR2 agonist from different bac-
terial LPS, induced distinct patterns of cytokine produc-
tion by macrophages [34]. Therefore, we can not rule out
the possibility of the ligation of TLR4 by different LPS or
bacterial endotoxins present in CS medium. However,
these compounds are part of CS extract and must be con-
sidered as one of the inflammatory stimuli of CS consti-
tutes which might triggers initial lung inflammation in
COPD.
In our study no analysis done to characterize the chemical
nature of the activity present in CS medium. For instance,
our CS medium may contain reactive oxygen species
(ROS) which activates NF-κB [44] and may regulate
immune signaling through TLR4. Further studies are
needed to address firstly the presence of ROS in our CS
medium preparations and secondly the possible ROS
interaction with TLR4 signaling.
During the preparation of the manuscript, Droemann et
al. [45] proposed a smoke related change in the pheno-
type of alveolar macrophages demonstrating a reduced
expression of TLR2 in smokers and COPD. Although the
alteration is restricted to TLR2 expression but supports the
hypothesis that COPD pathogenesis might be associated
to stimulation of macrophages through TLRs.
Peripheral blood monocyte-derived macrophages are a
unique cell type generated in vitro and are an attractive
cell model to study the role of macrophages in inflamma-
tory process. However, consideration of how the findings
can be linked to the human disease must be given. Indeed,
human alveolar macrophages can be employed to further
examine the validity of our findings in the context of
human disease.
Conclusion
Increased levels of IL-8 in patients with mild-to-moderate
COPD has been demonstrated suggesting that the migra-
tion of neutrophils and mononuclear cells from the bron-
chial wall to the lumen could be increased through IL-8
[3]. Our study suggests that in lungs, macrophage-derived
IL-8 after TLR engagement may trigger the recruitment of
neutrophils and CD8 positive T cells, both the major
effector cells in COPD inflammatory process. The clarifi-
cation of the mechanisms of macrophage activation by CS
through this TLR may offer new insight into the treatment
of COPD. In conclusion, our observations suggest a cellu-
lar mechanism that links smoking with inflammation in
COPD.
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